Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Prevention of myelotoxicity-every week during chemotherapy.
Georgeta Fried, MD
Principal Investigator
Rambam Health Care Campus
Israel: Israeli Health Ministry Pharmaceutical Administration
LifemelCTIL
NCT00243165
November 2005
Name | Location |
---|